Mega Lifesciences 1H26 slides: revenue up 12.5%, profit jumps 33%

Mega Lifesciences Public Company Limited reported impressive first-half 2026 financial results on September 1, 2026, with revenue up 12.5% year-over-year and net profit surging 33%. Based in Thailand and operating across Southeast Asia and Sub-Saharan Africa, the company's operating revenue reached THB 6,942 million, a 12.5% increase from the same period in 2025. Despite a slight 0.69% drop in stock price, the company's shares remained strong, trading at $35.75.

The growth was driven by both Mega We Care and Maxxcare segments. Mega We Care, a branded products business, generated THB 4,660 million in revenue, up 11.9% year-over-year. Maxxcare, a distribution business, contributed THB 2,070 million, reflecting an 11.3% increase. Management attributed the Maxxcare improvement to better operating conditions, particularly in Myanmar.

Gross margins expanded to 52.0% from 50.5% in the same period last year, driven by product mix, country mix, and operational efficiencies. EBITDA surged 33.8% to THB 1,613 million, and net profit increased 33.1% to THB 1,119 million. Adjusted net profit was THB 1,028 million, up 11.7% year-over-year.

The company's geographic diversification strategy also showed progress. Southeast Asia accounted for 73.3% of Mega We Care revenue, with the Indochina region contributing the most. Africa was the fastest-growing region, with a 29.6% year-over-year increase in revenue. Other markets, including Australia and the Middle East, saw a 40.7% increase in revenue.

Mega Lifesciences' financial position remained robust, with a net cash position of THB 3,487 million at the end of June 2026, down slightly from the previous year. The company maintained a healthy leverage ratio and strong cash flow characteristics, with operating cash flows averaging 118% of net profits from 2019 to 2025. The company's long-term growth strategy includes doubling consolidated net profits by 2030.